400 Clinical Researchers Release AI Benchmarking Report for Trial Operations
400 clinical researchers release AI Benchmarking Report for trial operations, establishing industry baseline standards for sponsor and site adoption.
Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Artificial Intelligence in Clinical Trials Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Innovation Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials protocol amendments Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
400 clinical researchers release AI Benchmarking Report for trial operations, establishing industry baseline standards for sponsor and site adoption.
Only 11% of pharma firms have fully implemented AI in clinical trials as of late 2024, according to WCG's...
Can-Fite's namodenoson met safety goals in Phase 2a pancreatic cancer study, with third-line patients showing median survival exceeding five...
The PARTNERS trial opened BVD enrollment July 2, 2026, testing MBP134 and obeldesivir for a hemorrhagic fever that kills...
A JAMA Psychiatry trial of inhaled mebufotenin in TRD shows rapid antidepressant response, and exposes critical gaps in how...
New preclinical data shows semaglutide cuts fentanyl self-administration in rats, and raises hard questions about OUD trial design for...
Imviva gains FDA clearance for clonoSEQ in CTD402 T-ALL trial, enabling MRD-driven patient management decisions in allogeneic CAR-T therapy...
Brii Bio's ENRICH study demonstrates 42.9% HBsAg loss in hepatitis B patients, but Phase 3 advancement faces legal constraints...
Revolution Medicines reports 82% response rate for zoldonrasib in metastatic pancreatic cancer, with Phase 3 trials underway in first-line...
Health AI acing benchmarks while failing real clinical tasks exposes a validation gap that trial sponsors and the FDA...